EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 271 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma June 6, 2025 New Research Discovers How Scalp Cooling Helps Chemo Patients Keep Their... February 6, 2021 Neoadjuvant Nivolumab Plus Ipilimumab Leads to a Pathological Response in a... June 12, 2024 New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers May 31, 2018 Load more HOT NEWS Woman with Breast Cancer May Have Saved Her Twin’s Life by... A tribute to Professor Gordon McVie The RAD51-IF Test Is Feasible for Assessment of the Functional Status... Using a Mind-Body Connection to Help You Cope During Cancer: An...
